Published in Ann Surg on January 01, 2005
microRNA-21 promotes tumor proliferation and invasion in gastric cancer by targeting PTEN. Oncol Rep (2012) 1.68
Rationale for gastrectomy with D2 lymphadenectomy in the treatment of gastric cancer. Gastric Cancer (2008) 1.44
Changes in treatment outcomes of gastric cancer surgery over 45 years at a single institution. Yonsei Med J (2008) 1.34
Laparoscopic total gastrectomy versus open total gastrectomy for cancer: a systematic review and meta-analysis. Surg Endosc (2012) 1.34
Survival of metastatic gastric cancer: Significance of age, sex and race/ethnicity. J Gastrointest Oncol (2011) 1.25
Lymphovascular invasion is associated with poor survival in gastric cancer: an application of gene-expression and tissue array techniques. Ann Surg (2006) 1.20
Integrative approach for differentially overexpressed genes in gastric cancer by combining large-scale gene expression profiling and network analysis. Br J Cancer (2008) 1.16
Chemotherapy for gastric cancer. World J Gastroenterol (2006) 1.13
Robotic versus Laparoscopic versus Open Gastrectomy: A Meta-Analysis. J Gastric Cancer (2013) 1.11
HER2 status in gastro-oesophageal adenocarcinomas assessed by two rabbit monoclonal antibodies (SP3 and 4B5) and two in situ hybridization methods (FISH and SISH). Histopathology (2011) 1.10
Immunohistochemical features of the gastrointestinal tract tumors. J Gastrointest Oncol (2012) 1.06
Laparoscopy-assisted versus open gastrectomy with D2 lymph node dissection for advanced gastric cancer: a meta-analysis. Int J Clin Exp Med (2014) 1.06
Discovery and validation of prognostic markers in gastric cancer by genome-wide expression profiling. World J Gastroenterol (2011) 1.05
Laparoscopy-assisted gastrectomy with D2 lymph node dissection for advanced gastric cancer without serosa invasion: a matched cohort study from South China. World J Surg Oncol (2013) 1.03
Robotic versus open gastrectomy for gastric cancer: a meta-analysis. PLoS One (2013) 1.03
Analysis of the prognostic factors and evaluation of surgical treatment for synchronous liver metastases from gastric cancer. Langenbecks Arch Surg (2008) 1.02
MYC, FBXW7 and TP53 copy number variation and expression in gastric cancer. BMC Gastroenterol (2013) 1.01
Stage-stratified analysis of prognostic significance of tumor size in patients with gastric cancer. PLoS One (2013) 1.01
Molecular classification of gastric cancer: Towards a pathway-driven targeted therapy. Oncotarget (2015) 0.97
Aberrant upregulation of 14-3-3ơ expression serves as an inferior prognostic biomarker for gastric cancer. BMC Cancer (2011) 0.97
Pathogenetic mechanisms in gastric cancer. World J Gastroenterol (2014) 0.97
Gastric cancer, Helicobacter pylori infection and other risk factors. World J Gastrointest Oncol (2010) 0.96
miR-449a Regulates proliferation and chemosensitivity to cisplatin by targeting cyclin D1 and BCL2 in SGC7901 cells. Dig Dis Sci (2013) 0.95
Soluble Fas might serve as a diagnostic tool for gastric adenocarcinoma. BMC Cancer (2010) 0.93
Impact of intraoperative blood loss on survival after curative resection for gastric cancer. World J Gastroenterol (2013) 0.92
Which Is the Optimal Extent of Resection in Middle Third Gastric Cancer between Total Gastrectomy and Subtotal Gastrectomy? J Gastric Cancer (2010) 0.92
Experience of surgical morbidity after palliative surgery in patients with gastric carcinoma. Gastric Cancer (2007) 0.91
Prognostic relevance of Period1 (Per1) and Period2 (Per2) expression in human gastric cancer. Int J Clin Exp Pathol (2014) 0.91
Comparison of laparoscopically assisted and open radical distal gastrectomy with extended lymphadenectomy for gastric cancer management. Surg Endosc (2006) 0.91
Decreased expression of microRNA let-7i and its association with chemotherapeutic response in human gastric cancer. World J Surg Oncol (2012) 0.91
Diagnostic accuracy of circulating tumor cells detection in gastric cancer: systematic review and meta-analysis. BMC Cancer (2013) 0.90
Activated mammalian target of rapamycin is a potential therapeutic target in gastric cancer. BMC Cancer (2010) 0.90
Survival trends in gastric cancer patients of Northeast China. World J Gastroenterol (2011) 0.90
A phase IIa dose-finding and safety study of first-line pertuzumab in combination with trastuzumab, capecitabine and cisplatin in patients with HER2-positive advanced gastric cancer. Br J Cancer (2014) 0.90
Clinicopathological profile and long-term outcome in young adults with gastric cancer: multicenter evaluation of 214 patients. Langenbecks Arch Surg (2007) 0.89
Quality of life, immunomodulation and safety of adjuvant mistletoe treatment in patients with gastric carcinoma - a randomized, controlled pilot study. BMC Complement Altern Med (2012) 0.89
Adverse prognostic impact of perioperative allogeneic transfusion on patients with stage II/III gastric cancer. Gastric Cancer (2015) 0.89
miR-101-2, miR-125b-2 and miR-451a act as potential tumor suppressors in gastric cancer through regulation of the PI3K/AKT/mTOR pathway. Cell Oncol (Dordr) (2015) 0.89
The Reliability of Endoscopic Biopsies in Assessing HER2 Status in Gastric and Gastroesophageal Junction Cancer: A Study Comparing Biopsies with Surgical Samples. Transl Oncol (2013) 0.88
Serum glycan signatures of gastric cancer. Cancer Prev Res (Phila) (2013) 0.88
Calcium calmodulin dependent kinase kinase 2 - a novel therapeutic target for gastric adenocarcinoma. Cancer Biol Ther (2015) 0.88
Gastric cancer cell lines induced by trichostatin A. World J Gastroenterol (2008) 0.88
Laparoscopic versus open gastrectomy for gastric cancer, a multicenter prospectively randomized controlled trial (LOGICA-trial). BMC Cancer (2015) 0.88
Post-operative complications of gastric cancer surgery: female gender at high risk. Eur J Cancer Care (Engl) (2009) 0.87
Adjuvant chemoradiotherapy after d2-lymphadenectomy for gastric cancer: the role of n-ratio in patient selection. results of a single cancer center. Radiat Oncol (2012) 0.87
Prognostic analysis of combined curative resection of the stomach and liver lesions in 30 gastric cancer patients with synchronous liver metastases. BMC Surg (2012) 0.87
High RSF-1 expression correlates with poor prognosis in patients with gastric adenocarcinoma. Int J Clin Exp Pathol (2012) 0.86
Gastric cancer research in Mexico: a public health priority. World J Gastroenterol (2014) 0.86
Quality of life: A critical outcome for all surgical treatments of gastric cancer. World J Gastroenterol (2016) 0.85
Is endoscopic ultrasonography still the modality of choice in preoperative staging of gastric cancer? World J Gastroenterol (2014) 0.85
Prognostic impact of venous invasion in stage IB node-negative gastric cancer. Gastric Cancer (2014) 0.85
Methylation of CpG sites in RNF180 DNA promoter prediction poor survival of gastric cancer. Oncotarget (2014) 0.85
Combined use of lysyl oxidase, carcino-embryonic antigen, and carbohydrate antigens improves the sensitivity of biomarkers in predicting lymph node metastasis and peritoneal metastasis in gastric cancer. Tumour Biol (2014) 0.85
Conditional survival analysis in Korean patients with gastric cancer undergoing curative gastrectomy. BMC Cancer (2015) 0.85
Mining novel biomarkers for prognosis of gastric cancer with serum proteomics. J Exp Clin Cancer Res (2009) 0.85
Crosstalk between Long Noncoding RNAs and MicroRNAs in Health and Disease. Int J Mol Sci (2016) 0.85
Regression of Gastric Cancer by Systemic Injection of RNA Nanoparticles Carrying both Ligand and siRNA. Sci Rep (2015) 0.84
Carcinogenic Helicobacter pylori in gastric pre-cancer and cancer lesions: association with tobacco-chewing. World J Gastroenterol (2014) 0.84
Role of vascular endothelial growth factor (VEGF) and VEGF-R genotyping in guiding the metastatic process in pT4a resected gastric cancer patients. PLoS One (2012) 0.84
Vincristine enhances amoeboid-like motility via GEF-H1/RhoA/ROCK/Myosin light chain signaling in MKN45 cells. BMC Cancer (2012) 0.84
Podocalyxin as a Prognostic Marker in Gastric Cancer. PLoS One (2015) 0.84
Analysis of lymph node metastasis correlation with prognosis in patients with T2 gastric cancer. PLoS One (2014) 0.84
Surgery for Liver Metastases From Gastric Cancer: A Meta-Analysis of Observational Studies. Medicine (Baltimore) (2015) 0.83
Low expression of SOCS-1 and SOCS-3 is a poor prognostic indicator for gastric cancer patients. J Cancer Res Clin Oncol (2014) 0.83
The Serum Immunoglobulin G Glycosylation Signature of Gastric Cancer. EuPA Open Proteom (2015) 0.83
Characterization of gastric adenocarcinoma cell lines established from CEA424/SV40 T antigen-transgenic mice with or without a human CEA transgene. BMC Cancer (2006) 0.83
Remodeling of the pulmonary artery induced by metastatic gastric carcinoma: a histopathological analysis of 51 autopsy cases. BMC Cancer (2014) 0.82
Endoscopic Raman Spectroscopy for Molecular Fingerprinting of Gastric Cancer: Principle to Implementation. Biomed Res Int (2015) 0.82
Biomarkers of Helicobacter pylori-associated gastric cancer. Gut Microbes (2013) 0.82
Preoperative tumor size is a critical prognostic factor for patients with Borrmann type III gastric cancer. Surg Today (2014) 0.81
Increased expression of cellular repressor of E1A-stimulated gene (CREG) in gastric cancer patients: a mechanism of proliferation and metastasis in cancer. Dig Dis Sci (2010) 0.81
Meta-analysis of immunohistochemical expression of hypoxia inducible factor-1α as a prognostic role in gastric cancer. World J Gastroenterol (2014) 0.81
Robust Detection of DNA Hypermethylation of ZNF154 as a Pan-Cancer Locus with in Silico Modeling for Blood-Based Diagnostic Development. J Mol Diagn (2016) 0.80
Stathmin is a potential molecular marker and target for the treatment of gastric cancer. Int J Clin Exp Med (2015) 0.80
Co-delivery of doxorubicin and SATB1 shRNA by thermosensitive magnetic cationic liposomes for gastric cancer therapy. PLoS One (2014) 0.80
PIAS3, an inhibitor of STAT3, has intensively negative association with the survival of gastric cancer. Int J Clin Exp Med (2015) 0.80
Clinicopathological significance of NMIIA overexpression in human gastric cancer. Int J Mol Sci (2012) 0.80
Expression of the matrix metalloproteases 2, 14, 24, and 25 and tissue inhibitor 3 as potential molecular markers in advanced human gastric cancer. Dis Markers (2014) 0.80
Effect of celecoxib plus standard chemotherapy on serum levels of vascular endothelial growth factor and cyclooxygenase-2 in patients with gastric cancer. Biomed Rep (2013) 0.80
Exome sequencing identifies early gastric carcinoma as an early stage of advanced gastric cancer. PLoS One (2013) 0.79
Evaluation of prognostic factors and survival results in gastric carcinoma: single center experience from Northeast Turkey. Int J Clin Exp Med (2014) 0.79
Identification of a new target region on the long arm of chromosome 7 in gastric carcinoma by loss of heterozygosity. World J Gastroenterol (2006) 0.79
Postoperative chemotherapy in gastric cancer, consisting of etoposide, doxorubicin and cisplatin, followed by radiotherapy with concomitant cisplatin: A feasibility study. Oncol Lett (2012) 0.79
MAGE-A protein and MAGE-A10 gene expressions in liver metastasis in patients with stomach cancer. Br J Cancer (2008) 0.79
Association of ezrin expression in intestinal and diffuse gastric carcinoma with clinicopathological parameters and tumor type. World J Gastroenterol (2007) 0.79
Discrimination of gastric cancer from normal by serum RNA based on surface-enhanced Raman spectroscopy (SERS) and multivariate analysis. Med Phys (2012) 0.78
HER2 in gastric cancer: comparative analysis of three different antibodies using whole-tissue sections and tissue microarrays. World J Gastroenterol (2013) 0.78
Localized gastric cancer: chemoradiation is not always needed. Gastrointest Cancer Res (2009) 0.77
Effect of neoadjuvant chemotherapy combined with hyperthermic intraperitoneal perfusion chemotherapy on advanced gastric cancer. Exp Ther Med (2014) 0.77
Relationship between 15-hydroxyprostaglandin dehydrogenase and gastric adenocarcinoma. Ann Surg Treat Res (2014) 0.77
DNA Methylation in the Exon 1 Region and Complex Regulation of Twist1 Expression in Gastric Cancer Cells. PLoS One (2015) 0.77
Expression of elongation factor (EF)-Tu is correlated with prognosis of gastric adenocarcinomas. Int J Mol Sci (2011) 0.77
Identification of a novel gene fusion (BMX-ARHGAP) in gastric cardia adenocarcinoma. Diagn Pathol (2014) 0.77
Brain metastases in gastrointestinal cancers: is there a role for surgery? Int J Mol Sci (2014) 0.77
Clinical significance of tumor expression of major histocompatibility complex class I-related chains A and B (MICA/B) in gastric cancer patients. Oncol Rep (2015) 0.77
Effect of Native Gastric Mucus on in vivo Hybridization Therapies Directed at Helicobacter pylori. Mol Ther Nucleic Acids (2015) 0.77
A Causal Role of Genetically Elevated Circulating Interleukin-10 in the Development of Digestive Cancers: Evidence from Mendelian Randomization Analysis Based on 29,307 Subjects. Medicine (Baltimore) (2016) 0.76
Length of negative resection margin does not affect local recurrence and survival in the patients with gastric cancer. World J Gastroenterol (2014) 0.76
Lack of association between the CDH1 polymorphism and gastric cancer susceptibility: a meta-analysis. Sci Rep (2015) 0.76
The hallmarks of cancer. Cell (2000) 113.05
Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci U S A (2001) 71.82
Gene expression profiling predicts clinical outcome of breast cancer. Nature (2002) 71.36
A gene-expression signature as a predictor of survival in breast cancer. N Engl J Med (2002) 58.15
Helicobacter pylori infection and the risk of gastric carcinoma. N Engl J Med (1991) 23.89
THE TWO HISTOLOGICAL MAIN TYPES OF GASTRIC CARCINOMA: DIFFUSE AND SO-CALLED INTESTINAL-TYPE CARCINOMA. AN ATTEMPT AT A HISTO-CLINICAL CLASSIFICATION. Acta Pathol Microbiol Scand (1965) 22.65
Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction. N Engl J Med (2001) 18.77
Analyzing high-density oligonucleotide gene expression array data. J Cell Biochem (2000) 16.73
Genomics, gene expression and DNA arrays. Nature (2000) 11.48
Changing patterns in the incidence of esophageal and gastric carcinoma in the United States. Cancer (1998) 10.17
Association between infection with Helicobacter pylori and risk of gastric cancer: evidence from a prospective investigation. BMJ (1991) 9.88
Differences in diagnostic criteria for gastric carcinoma between Japanese and western pathologists. Lancet (1997) 7.59
Extended lymph-node dissection for gastric cancer. N Engl J Med (1999) 7.43
Patient survival after D1 and D2 resections for gastric cancer: long-term results of the MRC randomized surgical trial. Surgical Co-operative Group. Br J Cancer (1999) 6.76
Systematic population-based assessment of cancer risk in first-degree relatives of cancer probands. J Natl Cancer Inst (1994) 6.27
Randomized trial comparing epirubicin, cisplatin, and fluorouracil versus fluorouracil, doxorubicin, and methotrexate in advanced esophagogastric cancer. J Clin Oncol (1997) 5.89
Gastric carcinoma. N Engl J Med (1995) 5.77
Adjuvant therapy after curative resection for gastric cancer: meta-analysis of randomized trials. J Clin Oncol (1993) 5.37
Modified therapy with 5-fluorouracil, doxorubicin, and methotrexate in advanced gastric cancer. Cancer (1993) 4.99
Randomised comparison of fluorouracil, epidoxorubicin and methotrexate (FEMTX) plus supportive care with supportive care alone in patients with non-resectable gastric cancer. Br J Cancer (1995) 4.99
Relevant prognostic factors in gastric cancer: ten-year results of the German Gastric Cancer Study. Ann Surg (1998) 4.86
Randomized comparison between chemotherapy plus best supportive care with best supportive care in advanced gastric cancer. Ann Oncol (1997) 4.69
Progress in gastric cancer surgery in Japan and its limits of radicality. World J Surg (1987) 4.06
Oligonucleotide microarray for prediction of early intrahepatic recurrence of hepatocellular carcinoma after curative resection. Lancet (2003) 3.93
Cancer of the stomach. A patient care study by the American College of Surgeons. Ann Surg (1993) 3.80
Adenocarcinoma of the stomach: are we making progress? Lancet (1993) 3.68
Molecular profiling of non-small cell lung cancer and correlation with disease-free survival. Cancer Res (2002) 3.68
Early gastric cancer in young, asymptomatic carriers of germ-line E-cadherin mutations. N Engl J Med (2001) 3.27
Association of Helicobacter pylori infection with gastric carcinoma: a meta-analysis. Am J Gastroenterol (1999) 3.01
Global gene expression analysis of gastric cancer by oligonucleotide microarrays. Cancer Res (2002) 2.49
DNA microarrays in clinical oncology. J Clin Oncol (2002) 2.40
Adjuvant chemotherapy after curative resection for gastric cancer in non-Asian patients: revisiting a meta-analysis of randomised trials. Eur J Cancer (1999) 2.36
Lymph node staging in gastric cancer: is location more important than Number? An analysis of 1,038 patients. Ann Surg (2000) 2.05
Chemotherapy in gastric cancer: a review and updated meta-analysis. Eur J Surg (2002) 2.04
Subtotal versus total gastrectomy for gastric cancer: five-year survival rates in a multicenter randomized Italian trial. Italian Gastrointestinal Tumor Study Group. Ann Surg (1999) 2.00
Pathology and prognosis of gastric carcinoma. Findings in 10,000 patients who underwent primary gastrectomy. Cancer (1992) 1.93
Value of palliative resection in gastric cancer. Br J Surg (2002) 1.90
Family history and the risk of stomach and colorectal cancer. Cancer (1992) 1.83
Effect of lymph node dissection on the prognosis in patients with node-negative early gastric cancer. Surgery (1995) 1.82
Global gene expression profiling in Barrett's esophagus and esophageal cancer: a comparative analysis using cDNA microarrays. Oncogene (2002) 1.54
c-erbB-2 is of independent prognostic relevance in gastric cancer and is associated with the expression of tumor-associated protease systems. J Clin Oncol (2000) 1.54
Adequacy of margins of resection in gastrectomy for cancer. Ann Surg (1982) 1.52
Postoperative adjuvant chemoradiation therapy for patients with resected gastric cancer: intergroup 116. J Clin Oncol (2000) 1.52
Differential gene expression profiles of scirrhous gastric cancer cells with high metastatic potential to peritoneum or lymph nodes. Cancer Res (2001) 1.50
Prognostic value of carcinoembryonic antigen, CA 19-9 and CA 72-4 in gastric carcinoma. Tumour Biol (2001) 1.49
Classification of regional lymph node metastasis from gastric carcinoma. German Gastric Cancer Study Group. Cancer (1998) 1.49
E-cadherin gene mutations provide a genetic basis for the phenotypic divergence of mixed gastric carcinomas. Lab Invest (1999) 1.47
Neoadjuvant or adjuvant therapy for resectable gastric cancer? A practice guideline. Can J Surg (2002) 1.47
Combined 5-fluorouracil and radiation therapy as a surgical adjuvant for poor prognosis gastric carcinoma. J Clin Oncol (1984) 1.46
A systematic overview of chemotherapy effects in gastric cancer. Acta Oncol (2001) 1.46
Total gastrectomy is not necessary for proximal gastric cancer. Surgery (1998) 1.46
Genome-wide analysis of gene expression in intestinal-type gastric cancers using a complementary DNA microarray representing 23,040 genes. Cancer Res (2002) 1.46
Endoscopic ultrasonography in the preoperative staging of gastric cancer: accuracy and impact on surgical therapy. Surg Endosc (2000) 1.43
Gene expression profile analysis by DNA microarrays: promise and pitfalls. JAMA (2001) 1.41
Prognostic impact of lymphatic and/or blood vessel invasion in patients with node-negative advanced gastric cancer. Ann Surg Oncol (2002) 1.40
Biologic predictors of survival in node-negative gastric cancer. Ann Surg (2003) 1.37
Survival benefit of extended D2 lymphadenectomy in gastric cancer with involvement of second level lymph nodes: a longitudinal multicenter study. Ann Surg Oncol (2002) 1.34
Asian patients with gastric carcinoma in the United States exhibit unique clinical features and superior overall and cancer specific survival rates. Cancer (2000) 1.33
Staging of gastric cancer: correlation of lymph node size and metastatic infiltration. AJR Am J Roentgenol (1999) 1.23
Expression profiling of gastric adenocarcinoma using cDNA array. Int J Cancer (2001) 1.23
Prognostic factors after curative resection for gastric cancer. A population-based study. Eur J Cancer (2000) 1.22
Results of gastric resection for carcinoma of the stomach: the European experience. World J Surg (1988) 1.21
Comparing MR imaging and CT in the staging of gastric carcinoma. AJR Am J Roentgenol (2000) 1.21
The difference in gastric cancer between Japan, USA and Europe: what are the facts? what are the suggestions? Crit Rev Oncol Hematol (2001) 1.20
The use of molecular biology in diagnosis and prognosis of gastric cancer. Surg Oncol (2000) 1.20
Molecular diagnosis of gastric cancer: present and future. Gastric Cancer (2001) 1.18
Prognostic score of gastric cancer determined by cDNA microarray. Clin Cancer Res (2002) 1.16
The number of metastatic lymph nodes: a promising prognostic determinant for gastric carcinoma in the latest edition of the TNM classification. J Am Coll Surg (1998) 1.16
Adenocarcinoma of the stomach: univariate and multivariate analysis of factors associated with survival. Am J Clin Oncol (2002) 1.15
Changing pattern of histological type, location, stage and outcome of surgical treatment of gastric carcinoma. Br J Surg (2000) 1.14
Intravenous chemotherapy for resected gastric cancer: meta-analysis of randomized controlled trials. World J Gastroenterol (2002) 1.12
Profiling of differentially expressed genes in human gastric carcinoma by cDNA expression array. World J Gastroenterol (2002) 1.11
Comprehensive analysis of the gene expression profiles in human gastric cancer cell lines. Oncogene (2002) 1.11
Extended lymphadenectomy is associated with a survival benefit for node-negative gastric cancer. J Gastrointest Surg (1999) 1.09
Significant prognostic factors in patients with early gastric cancer. Int Surg (2001) 1.09
Invasion and metastases in gastric cancer: in vitro and in vivo models with clinical correlations. Semin Oncol (1996) 1.08
Surgical treatment of gastric adenocarcinoma: impact on survival and quality of life. A prospective ten year study. Hepatogastroenterology (1996) 1.06
Quality of life and functional results following different types of resection for gastric carcinoma. Eur J Surg Oncol (1990) 1.05
Impact of surgical procedure for gastric cancer on quality of life. Br J Surg (2003) 1.05
Clinicopathological characteristics of gastric carcinoma in young and elderly patients: a comparative study. Ann Surg Oncol (2000) 1.04
Current options in the management of gastrointestinal cancer. Ann Oncol (1995) 1.03
Dietary factors and gastric cancer risk. A case-control study in Spain. Cancer (1993) 1.02
Gastric adenocarcinoma: pathomorphology and molecular pathology. J Cancer Res Clin Oncol (2001) 1.02
Current status of surgical treatment of gastric cancer. J Surg Oncol (2002) 1.01
Meta-analyses of randomized trials of adjuvant chemotherapy in gastric cancer. Ann Oncol (2001) 1.01
Adjuvant treatment in gastric cancer. Cancer Treat Rev (1994) 1.01
Prospective randomized trial of combined oncological therapy for gastric carcinoma. Cancer (1979) 1.01
Outcome of patients with proximal gastric cancer depends on extent of resection and number of resected lymph nodes. Ann Surg Oncol (2000) 1.00
Minimum number of lymph nodes that should be examined for the International Union Against Cancer/American Joint Committee on Cancer TNM classification of gastric carcinoma. World J Surg (2003) 0.99
Neoadjuvant chemotherapy for high-grade advanced gastric cancer. World J Surg (1993) 0.99
Identification of genes differentially expressed between gastric cancers and normal gastric mucosa with cDNA microarrays. Cancer Lett (2002) 0.99
Survival benefit of D2 lympadenectomy in patients with gastric adenocarcinoma. Ann Surg Oncol (2000) 0.98
Involvement of three or more lymph nodes predicts poor prognosis in submucosal gastric carcinoma. Gastric Cancer (2001) 0.97
Surgery: independent prognostic factor in curable and far advanced gastric cancer. World J Surg (2000) 0.97
Extended (D2) lymph node dissection for gastric cancer: do patients benefit? Ann Surg Oncol (2000) 0.97
Inactivation of the E-cadherin gene in sporadic diffuse-type gastric cancer. Mod Pathol (2001) 0.96
Lymphadenectomy in gastric cancer: prognostic role and therapeutic implications. Eur J Surg Oncol (2002) 0.96
Evaluating survivorship care plans: results of a randomized, clinical trial of patients with breast cancer. J Clin Oncol (2011) 5.67
Effects of exercise on breast cancer patients and survivors: a systematic review and meta-analysis. CMAJ (2006) 4.79
Evaluation of tumor response, disease control, progression-free survival, and time to progression as potential surrogate end points in metastatic breast cancer. J Clin Oncol (2008) 4.24
Effects of aerobic and resistance exercise in breast cancer patients receiving adjuvant chemotherapy: a multicenter randomized controlled trial. J Clin Oncol (2007) 3.58
Randomized controlled trial of exercise training in postmenopausal breast cancer survivors: cardiopulmonary and quality of life outcomes. J Clin Oncol (2003) 3.56
Sirolimus-based immunosuppression is associated with increased survival after liver transplantation for hepatocellular carcinoma. Hepatology (2010) 3.54
Human equilibrative nucleoside transporter 1 levels predict response to gemcitabine in patients with pancreatic cancer. Gastroenterology (2008) 3.28
Sarcopenia as a determinant of chemotherapy toxicity and time to tumor progression in metastatic breast cancer patients receiving capecitabine treatment. Clin Cancer Res (2009) 3.06
Randomized controlled trial of the effects of print materials and step pedometers on physical activity and quality of life in breast cancer survivors. J Clin Oncol (2007) 2.65
Early breast cancer therapy and cardiovascular injury. J Am Coll Cardiol (2007) 2.53
Prognostic significance of human epidermal growth factor receptor positivity for the development of brain metastasis after newly diagnosed breast cancer. J Clin Oncol (2006) 2.51
Reassessing selection criteria prior to liver transplantation for hepatocellular carcinoma utilizing the Scientific Registry of Transplant Recipients database. Hepatology (2009) 2.51
Nucleoside analogues and nucleobases in cancer treatment. Lancet Oncol (2002) 2.23
The absence of human equilibrative nucleoside transporter 1 is associated with reduced survival in patients with gemcitabine-treated pancreas adenocarcinoma. Clin Cancer Res (2004) 2.06
Effects of an oncologist's recommendation to exercise on self-reported exercise behavior in newly diagnosed breast cancer survivors: a single-blind, randomized controlled trial. Ann Behav Med (2004) 2.04
Total tumor volume predicts risk of recurrence following liver transplantation in patients with hepatocellular carcinoma. Liver Transpl (2008) 2.04
Effect of anastrozole on bone mineral density: 5-year results from the anastrozole, tamoxifen, alone or in combination trial 18233230. J Clin Oncol (2008) 1.99
Effects of exercise training on fasting insulin, insulin resistance, insulin-like growth factors, and insulin-like growth factor binding proteins in postmenopausal breast cancer survivors: a randomized controlled trial. Cancer Epidemiol Biomarkers Prev (2003) 1.89
Randomized, placebo-controlled, double-blind, phase II study of axitinib plus docetaxel versus docetaxel plus placebo in patients with metastatic breast cancer. J Clin Oncol (2011) 1.87
Sirolimus-based immunosuppression for liver transplantation in the presence of extended criteria for hepatocellular carcinoma. Liver Transpl (2004) 1.80
Cardiorespiratory exercise testing in clinical oncology research: systematic review and practice recommendations. Lancet Oncol (2008) 1.79
Taxanes alone or in combination with anthracyclines as first-line therapy of patients with metastatic breast cancer. J Clin Oncol (2008) 1.76
Low serum albumin levels and liver metastasis are powerful prognostic markers for survival in patients with carcinomas of unknown primary site. Cancer (2006) 1.75
Exercise intolerance in cancer and the role of exercise therapy to reverse dysfunction. Lancet Oncol (2009) 1.75
Prevention of aromatase inhibitor-induced bone loss using risedronate: the SABRE trial. J Clin Oncol (2010) 1.74
Levels of gemcitabine transport and metabolism proteins predict survival times of patients treated with gemcitabine for pancreatic adenocarcinoma. Gastroenterology (2012) 1.67
DEAD box 1: a novel and independent prognostic marker for early recurrence in breast cancer. Breast Cancer Res Treat (2010) 1.65
The role of 2-deoxy-2-[F-18]fluoro-D-glucose positron emission tomography in disseminated carcinoma of unknown primary site. Cancer (2007) 1.63
Human equilibrative nucleoside transporter 1 and human concentrative nucleoside transporter 3 predict survival after adjuvant gemcitabine therapy in resected pancreatic adenocarcinoma. Clin Cancer Res (2009) 1.62
Cardiopulmonary function and age-related decline across the breast cancer survivorship continuum. J Clin Oncol (2012) 1.61
Effect of capecitabine on mean corpuscular volume in patients with metastatic breast cancer. Am J Clin Oncol (2004) 1.60
Motesanib, or open-label bevacizumab, in combination with paclitaxel, as first-line treatment for HER2-negative locally recurrent or metastatic breast cancer: a phase 2, randomised, double-blind, placebo-controlled study. Lancet Oncol (2011) 1.59
Gefitinib or placebo in combination with tamoxifen in patients with hormone receptor-positive metastatic breast cancer: a randomized phase II study. Clin Cancer Res (2011) 1.56
Pancreatic cancer hENT1 expression and survival from gemcitabine in patients from the ESPAC-3 trial. J Natl Cancer Inst (2013) 1.54
Cardiopulmonary resuscitation with chest compressions during sustained inflations: a new technique of neonatal resuscitation that improves recovery and survival in a neonatal porcine model. Circulation (2013) 1.51
Can quantifying hormone receptor levels guide the choice of adjuvant endocrine therapy for breast cancer? J Clin Oncol (2011) 1.48
Effect of exercise training on C-reactive protein in postmenopausal breast cancer survivors: a randomized controlled trial. Brain Behav Immun (2005) 1.45
Effects of presurgical exercise training on cardiorespiratory fitness among patients undergoing thoracic surgery for malignant lung lesions. Cancer (2007) 1.41
Postresuscitation administration of doxycycline preserves cardiac contractile function in hypoxia-reoxygenation injury of newborn piglets*. Crit Care Med (2014) 1.40
Universal screening for methicillin-resistant Staphylococcus aureus in surgical patients. J Am Coll Surg (2010) 1.38
Percutaneous transhepatic pancreatic islet cell transplantation in type 1 diabetes mellitus: radiologic aspects. Radiology (2003) 1.34
Strategic opportunities in clinical islet transplantation. Transplantation (2005) 1.34
Estrogen receptor expression and efficacy of docetaxel-containing adjuvant chemotherapy in patients with node-positive breast cancer: results from a pooled analysis. J Clin Oncol (2008) 1.33
Prospective cohort study of lifetime physical activity and breast cancer survival. Int J Cancer (2009) 1.32
Modulation of anthracycline-induced cardiotoxicity by aerobic exercise in breast cancer: current evidence and underlying mechanisms. Circulation (2011) 1.30
Randomized controlled trial of exercise and blood immune function in postmenopausal breast cancer survivors. J Appl Physiol (1985) (2005) 1.29
Resistance to gemcitabine in a human follicular lymphoma cell line is due to partial deletion of the deoxycytidine kinase gene. BMC Pharmacol (2004) 1.23
Predictors of supervised exercise adherence during breast cancer chemotherapy. Med Sci Sports Exerc (2008) 1.23
Beta1-integrin circumvents the antiproliferative effects of trastuzumab in human epidermal growth factor receptor-2-positive breast cancer. Cancer Res (2009) 1.21
Lymphovascular invasion is associated with poor survival in gastric cancer: an application of gene-expression and tissue array techniques. Ann Surg (2006) 1.20
Senescence evasion by MCF-7 human breast tumor-initiating cells. Breast Cancer Res (2010) 1.19
Safety and feasibility of cardiopulmonary exercise testing in patients with advanced cancer. Lung Cancer (2006) 1.19
Effects of exercise dose and type during breast cancer chemotherapy: multicenter randomized trial. J Natl Cancer Inst (2013) 1.18
Physical exercise and immune system function in cancer survivors: a comprehensive review and future directions. Cancer (2002) 1.18
Exercise for breast cancer survivors: research evidence and clinical guidelines. Phys Sportsmed (2002) 1.16
Cardiovascular risk profile of patients with HER2/neu-positive breast cancer treated with anthracycline-taxane-containing adjuvant chemotherapy and/or trastuzumab. Cancer Epidemiol Biomarkers Prev (2007) 1.16
Barriers to supervised exercise training in a randomized controlled trial of breast cancer patients receiving chemotherapy. Ann Behav Med (2008) 1.16
Cognitive effects of Tamoxifen in pre-menopausal women with breast cancer compared to healthy controls. J Cancer Surviv (2008) 1.16
Moderators of the effects of exercise training in breast cancer patients receiving chemotherapy: a randomized controlled trial. Cancer (2008) 1.15
Analyzing theoretical mechanisms of physical activity behavior change in breast cancer survivors: results from the activity promotion (ACTION) trial. Ann Behav Med (2008) 1.15
Cancer therapy-induced cardiac toxicity in early breast cancer: addressing the unresolved issues. Circulation (2012) 1.14
De novo sirolimus-based immunosuppression after liver transplantation for hepatocellular carcinoma: long-term outcomes and side effects. Transplantation (2007) 1.11
Predictors of follow-up exercise behavior 6 months after a randomized trial of exercise training during breast cancer chemotherapy. Breast Cancer Res Treat (2008) 1.10
cN-II expression predicts survival in patients receiving gemcitabine for advanced non-small cell lung cancer. Lung Cancer (2005) 1.09
Effects of exercise training on antitumor efficacy of doxorubicin in MDA-MB-231 breast cancer xenografts. Clin Cancer Res (2005) 1.09
In the end what matters most? A review of clinical endpoints in advanced breast cancer. Oncologist (2011) 1.09
Deoxycitidine kinase is associated with prolonged survival after adjuvant gemcitabine for resected pancreatic adenocarcinoma. Cancer (2010) 1.09
Class III beta-tubulin is a marker of paclitaxel resistance in carcinomas of unknown primary site. Cancer Chemother Pharmacol (2006) 1.09
Potential novel candidate polymorphisms identified in genome-wide association study for breast cancer susceptibility. Hum Genet (2011) 1.08
An exploratory study of body composition as a determinant of epirubicin pharmacokinetics and toxicity. Cancer Chemother Pharmacol (2010) 1.08
Six-month follow-up of patient-rated outcomes in a randomized controlled trial of exercise training during breast cancer chemotherapy. Cancer Epidemiol Biomarkers Prev (2007) 1.07
Adjuvant trastuzumab induces ventricular remodeling despite aerobic exercise training. Clin Cancer Res (2009) 1.04
Association of FABP5 expression with poor survival in triple-negative breast cancer: implication for retinoic acid therapy. Am J Pathol (2011) 1.03
Oncologists' opinions towards recommending exercise to patients with cancer: a Canadian national survey. Support Care Cancer (2005) 1.03
Prognostic role of human equilibrative transporter 1 (hENT1) in patients with resected gastric cancer. J Cell Physiol (2010) 1.02
Conservative and dietary interventions for cancer-related lymphedema: a systematic review and meta-analysis. Cancer (2010) 1.02
Cardiovascular reserve and risk profile of postmenopausal women after chemoendocrine therapy for hormone receptor--positive operable breast cancer. Oncologist (2007) 1.01
Deoxycytidine kinase and cN-II nucleotidase expression in blast cells predict survival in acute myeloid leukaemia patients treated with cytarabine. Br J Haematol (2003) 1.00
Sputum microRNA profiling: a novel approach for the early detection of non-small cell lung cancer. Clin Invest Med (2012) 1.00
Effects of exercise during adjuvant chemotherapy on breast cancer outcomes. Med Sci Sports Exerc (2014) 0.99
Signal transducers and activators of transcription-3 up-regulates tissue inhibitor of metalloproteinase-1 expression and decreases invasiveness of breast cancer. Am J Pathol (2006) 0.99
Exercise issues in older cancer survivors. Crit Rev Oncol Hematol (2004) 0.99
The role of membrane transporters in cellular resistance to anticancer nucleoside drugs. Cancer Treat Res (2002) 0.99
Does the theory of planned behavior mediate the effects of an oncologist's recommendation to exercise in newly diagnosed breast cancer survivors? Results from a randomized controlled trial. Health Psychol (2005) 0.97
Maintenance of physical activity in breast cancer survivors after a randomized trial. Med Sci Sports Exerc (2008) 0.97
Effects of aerobic exercise training in anemic cancer patients receiving darbepoetin alfa: a randomized controlled trial. Oncologist (2008) 0.97
Ramucirumab (IMC-1121B): a novel attack on angiogenesis. Future Oncol (2010) 0.97
Effects of aerobic exercise training on estrogen metabolism in premenopausal women: a randomized controlled trial. Cancer Epidemiol Biomarkers Prev (2007) 0.97